Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Amundi

Amundi boosted its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 137.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,030 shares of the company’s stock after buying an additional 15,624 shares during the quarter. Amundi’s holdings in Arcus Biosciences were worth $403,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Arcus Biosciences in the 4th quarter valued at about $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Arcus Biosciences during the 3rd quarter valued at about $47,000. US Bancorp DE grew its position in shares of Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after buying an additional 6,615 shares during the last quarter. Quest Partners LLC grew its position in shares of Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Arcus Biosciences during the 3rd quarter valued at about $244,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Price Performance

NYSE:RCUS opened at $9.05 on Friday. Arcus Biosciences, Inc. has a 12 month low of $8.82 and a 12 month high of $19.11. The firm has a market cap of $951.81 million, a PE ratio of -2.87 and a beta of 1.36. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The company’s 50-day moving average price is $11.77 and its two-hundred day moving average price is $14.68.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. On average, equities analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Insider Activity

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Yasunori Kaneko purchased 20,000 shares of Arcus Biosciences stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the purchase, the director now owns 28,400 shares in the company, valued at $285,704. This represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on RCUS. Morgan Stanley decreased their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. Finally, Bank of America decreased their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Arcus Biosciences presently has an average rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.